Elicio Therapeutics (9HA) Stock Overview
A clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
9HA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Elicio Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.90 |
| 52 Week High | US$11.90 |
| 52 Week Low | US$6.20 |
| Beta | 1.44 |
| 1 Month Change | 41.67% |
| 3 Month Change | 24.61% |
| 1 Year Change | 75.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 85.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9HA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 24.0% | 0.1% | -2.6% |
| 1Y | 75.0% | -7.7% | -1.4% |
Return vs Industry: 9HA exceeded the German Biotechs industry which returned -8% over the past year.
Return vs Market: 9HA exceeded the German Market which returned -0.8% over the past year.
Price Volatility
| 9HA volatility | |
|---|---|
| 9HA Average Weekly Movement | 15.7% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 9HA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9HA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 33 | Bob Connelly | elicio.com |
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers.
Elicio Therapeutics, Inc. Fundamentals Summary
| 9HA fundamental statistics | |
|---|---|
| Market cap | €226.30m |
| Earnings (TTM) | -€34.81m |
| Revenue (TTM) | n/a |
Is 9HA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9HA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$40.19m |
| Earnings | -US$40.18m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.18 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -659.4% |
How did 9HA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 17:49 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elicio Therapeutics, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Soumit Roy | JonesTrading Institutional Services, LLC |
| Boris Peaker | JonesTrading Institutional Services, LLC |